These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 37349124)

  • 1. circ-0000512 inhibits PD-L1 ubiquitination through sponging miR-622/CMTM6 axis to promote triple-negative breast cancer and immune escape.
    Dong LF; Chen FF; Fan YF; Zhang K; Chen HH
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37349124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Plasma exosomal miR-335-5p serves as a diagnostic indicator and inhibits immune escape in triple-negative breast cancer].
    Chen T; Dong Y; Wu X
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Apr; 38(4):347-356. PubMed ID: 35583065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circ_0000520 contributes to triple-negative breast cancer progression through mediating the miR-1296/ZFX axis.
    Zhou Y; Ma G; Peng S; Tuo M; Li Y; Qin X; Yu Q; Kuang S; Cheng H; Li J
    Thorac Cancer; 2021 Sep; 12(18):2427-2438. PubMed ID: 34324278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circular RNA circ-ZEB1 acts as an oncogene in triple negative breast cancer via sponging miR-448.
    Pei X; Zhang Y; Wang X; Xue B; Sun M; Li H
    Int J Biochem Cell Biol; 2020 Sep; 126():105798. PubMed ID: 32629026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circ_0007422 Knockdown Inhibits Tumor Property and Immune Escape of Colorectal Cancer by Decreasing PDL1 Expression in a miR-1256-Dependent Manner.
    Yin D; Yang L; Feng X; Zhai X; Hua M; Liu J; Chen Y
    Mol Biotechnol; 2024 Sep; 66(9):2606-2619. PubMed ID: 38253900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circular RNA circ-CPA4/ let-7 miRNA/PD-L1 axis regulates cell growth, stemness, drug resistance and immune evasion in non-small cell lung cancer (NSCLC).
    Hong W; Xue M; Jiang J; Zhang Y; Gao X
    J Exp Clin Cancer Res; 2020 Aug; 39(1):149. PubMed ID: 32746878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Silencing of COL3A1 represses proliferation, migration, invasion, and immune escape of triple negative breast cancer cells via down-regulating PD-L1 expression.
    Yang F; Lin L; Li X; Wen R; Zhang X
    Cell Biol Int; 2022 Nov; 46(11):1959-1969. PubMed ID: 35930601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hsa_circ_0001925 promotes malignant progression in triple-negative breast cancer via miR-1299/YY1 axis.
    Shen BJ; Yang YF; Zhang XX
    Thorac Cancer; 2023 Mar; 14(8):746-757. PubMed ID: 36754085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circ_0041732 regulates tumor properties of triple-negative breast cancer cells by the miR-149-5p/FGF5 pathway.
    Li H; Yin H; Yan Y
    Int J Biol Markers; 2022 Jun; 37(2):178-190. PubMed ID: 35341378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circular RNA hsa_circ_0067842 facilitates tumor metastasis and immune escape in breast cancer through HuR/CMTM6/PD-L1 axis.
    Li J; Dong X; Kong X; Wang Y; Li Y; Tong Y; Zhao W; Duan W; Li P; Wang Y; Wang C
    Biol Direct; 2023 Aug; 18(1):48. PubMed ID: 37592296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circ-CSNK1G1 promotes cell proliferation, migration, invasion and glycolysis metabolism during triple-negative breast cancer progression by modulating the miR-28-5p/LDHA pathway.
    Zan X; Li W; Wang G; Yuan J; Ai Y; Huang J; Li Z
    Reprod Biol Endocrinol; 2022 Sep; 20(1):138. PubMed ID: 36109751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CircRNA VIM silence synergizes with sevoflurane to inhibit immune escape and multiple oncogenic activities of esophageal cancer by simultaneously regulating miR-124/PD-L1 axis.
    Gao C; Xu YJ; Qi L; Bao YF; Zhang L; Zheng L
    Cell Biol Toxicol; 2022 Oct; 38(5):825-845. PubMed ID: 34018092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N
    Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
    Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hsa_circ_0136666 activates Treg-mediated immune escape of colorectal cancer via miR-497/PD-L1 pathway.
    Xu YJ; Zhao JM; Gao C; Ni XF; Wang W; Hu WW; Wu CP
    Cell Signal; 2021 Oct; 86():110095. PubMed ID: 34320370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hsa_circ_0136666 stimulates gastric cancer progression and tumor immune escape by regulating the miR-375/PRKDC Axis and PD-L1 phosphorylation.
    Miao Z; Li J; Wang Y; Shi M; Gu X; Zhang X; Wei F; Tang X; Zheng L; Xing Y
    Mol Cancer; 2023 Dec; 22(1):205. PubMed ID: 38093288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circ-METTL15 contributes to the proliferation, metastasis, immune escape and restrains apoptosis in lung cancer by regulating miR-1299/PDL1 axis.
    Zhang R; Shang L; Nan J; Niu K; Dai J; Jin X; Zhang X
    Autoimmunity; 2022 Feb; 55(1):8-20. PubMed ID: 34796777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 downregulates PD-L1 expression via miR-34a to inhibit the growth of triple-negative breast cancer cells: a potential clinical immunotherapeutic target.
    Deng S; Wang M; Wang C; Zeng Y; Qin X; Tan Y; Liang B; Cao Y
    Mol Biol Rep; 2023 Jan; 50(1):577-587. PubMed ID: 36352176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer cell-derived exosomal miR-20a-5p inhibits CD8
    Li W; Han G; Li F; Bu P; Hao Y; Huang L; Bai X
    Cancer Sci; 2024 Feb; 115(2):347-356. PubMed ID: 38129137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LncRNA GATA3-AS1 facilitates tumour progression and immune escape in triple-negative breast cancer through destabilization of GATA3 but stabilization of PD-L1.
    Zhang M; Wang N; Song P; Fu Y; Ren Y; Li Z; Wang J
    Cell Prolif; 2020 Sep; 53(9):e12855. PubMed ID: 32687248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circ_0001777 Affects Triple-negative Breast Cancer Progression Through the miR-95-3p/AKAP12 Axis.
    Chen Z; Gong X; Cheng C; Fu Y; Wu W; Luo Z
    Clin Breast Cancer; 2023 Feb; 23(2):143-154. PubMed ID: 36513585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.